/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,.
transformative and positively impacting their families and caregivers.”
Samantha has a strong track record in patient advocacy and gene therapy development, with deep experience in the development of natural history studies, registries, novel patient centered outcomes, and early access planning as well as access to collaborative networks. She previously served as Chief Patient Access Officer at Lysogene, and prior to that, was Director of External Affairs and Rare Disease Partnerships at Orphan Europe. Samantha was a founding member of several pilot European Reference Networks - virtual networks of healthcare providers aiming to facilitate discussion on complex or rare diseases. Samantha is also active in several scientific and healthcare-related organizations including the International Rare Disease Research Consortium (IRDiRC). She earned an MBA in Life Sciences from Open University’s School of Business, an International Management Degree from ESSEC Business School, and a B
Sierra Oncology Announces Abstracts Accepted for American Society of Clinical Oncology Annual Meeting
News provided by
Share this article
independence and overall survival to be presented
SAN MATEO, Calif., May 19, 2021
May 19, 2021 - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced three abstracts have been accepted into the program for the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held virtually from June 4-8, 2021.
Association of Transfusion Independence with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib
Dr. Ruben Mesa, MD, Director of the Mays Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, will present a poster examining the association between transfusion independence and overall survival for momelotinib patients from SIMPLIFY-1 (JAKi-naïve) and SIMPLIFY-2 (JAKi-exposed).
/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,.
Szklarski to discuss immigration and populism in Poland, Hungary and U S ampoleagle.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ampoleagle.com Daily Mail and Mail on Sunday newspapers.